Blog

Home  /  Outputs   /  EUnetHTA Joint Action 3 (2016-20)   /  Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)”.

The final version of the assessment was published in January 2018. Below is the documentation provided by the Joint Assessment authoring team:

PTJA03 Alectinib Final Assessment Report
Input from external expert and manufacturer on the 2nd draft assessment Alecensa PTJA03 (FINAL)
Project plan_PTJA03_Alectinib_final_0